Older patients may have to pass on the heartburn drugs to spare their bones from fractures according to a new study. According to a presentation at this year's Digestive Disease Week 2009, even short-term use of popular acid-reducing heartburn drugs may raise the risk of hip fractures. The increased risks appeared two years after patients started taking proton pump inhibitors such as Prevacid and histamine-2 receptor antagonists, or H2RAs, such as Zantac and Tagamet. Other proton pump inhibitors include popular brands such as Nexium, Prilosec, Protonix, and Aciphex. The study suggests long-term use of proton pump inhibitors -- for at least five years -- may raise the risk of hip fractures.
Rampant Disease Osteoporosis: Under-diagnosed, Under-treated - Experts Call For Earlier Diagnosis And Therapy
"With a continuously ageing population the incidence of osteoporosis is steadily rising. This does not only pose problems to the individuals concerned but is also an enormous challenge for our societies" according to Professor Wolfhart Puhl, past president of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT). Prof. Puhl, of the OrthopĂ dikum AllgĂ u, Germany, who is in Vienna for the EFORT Congress, emphasized that the problem's "dimension is frequently underestimated. Policy makers and funding agencies do not always consider this development sufficiently in their planning." More than 8, 000 participants from throughout the world are coming together for this major scientific event at the Austrian capital between 3 and 6 June, 2009.
FDA Approves Reclast R To Prevent Osteoporosis In Postmenopausal Women With Convenient Less Frequent Dosing
Reclast® (zoledronic acid 5 mg) Injection* has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose1. Reclast, or Aclasta® as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis1, 4. The FDA decision is based on a study involving more than 500 postmenopausal women with osteopenia, or low bone mass, showing that a single infusion of Reclast significantly increased bone mineral density (BMD) at two years compared to placebo1.
It's a sign of the times, as more and more people use cell or mobile phones and other high tech equipment they are more likely to end up with what the lay press calls cell phone elbow and what the doctors call cubital tunnel syndrome. What Is Cubital Tunnel Syndrome? Cubital tunnel syndrome is the second most common nerve compression syndrome in the upper extremities after carpal tunnel syndrome, say Dr Peter J Evans, Director of the Hand and Upper Extremity Center at the Cleveland Clinic in Ohio, USA, and colleagues in a question and answer article on the subject in a recent issue of the Cleveland Clinic Journal of Medicine. The article also covers diagnosis and treatment.
In children with the rare disease Pfeiffer syndrome, craniofacial surgery to correct skull defects is followed by a distinct pattern of increases in body temperature, reports a study in the January Journal of Craniofacial Surgery. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Together with previous studies, the results suggest that the postoperative temperature spikes are normal after surgery to correct craniosynostosis even when the skull defect is the only abnormality, and not part of a larger syndrome like Pfeiffer syndrome.
This study examined the 20-year follow-up of the cemented Anatomical Graduated Component total knee replacement carried out between 1983 and 2004. The results showed that the overall survival rate at 20 years was 97.8% with revision of the tibial or femoral component as the endpoint. The survival rate at 20 years of the tibial component was 98.3% and the femoral component was 99.4%. None of the 36 implants at the 20 year follow-up had been revised for polyethylene wear or osteolysis, which may be a reflection of the use of a non-modular, compression-moulded polyethylene implant, since other studies have found polyethylene wear to be a leading cause of failure leading to revision.